Table 1.
The inhibitors for mTORC1/2 complexes that are being tested alone or in combination with other therapeutics in different phases of clinical trials for several known malignancies
| mTOR inhibitor |
Combinational therapy | Type of cancer/diseases | Clinical status | References/ClinicalTrials ID |
|---|---|---|---|---|
| AZD2014 | N/A | Glioblastoma Multiforme | Phase 1 | NCT02619864 |
| AZD2014 | Anastrozole | Hormone Receptor-Positive endometrial carcinoma | Phase 1 & 2 | NCT02730923 |
| AZD2014 | Olaparib and AZD5363 |
Breast Cancer Malignant Female Reproductive System Neoplasm |
Phase 1 & 2 | NCT02208375 |
| Everolimus (RAD001) | N/A | Prostate Cancer Patients with Detectable PSA Following Prostatectomy | Phase 1 | NCT01548807 |
| AZD2014 | N/A | NF2 Patients with Progressive or Symptomatic Meningiomas | Phase 2 | NCT02831257 |
| Vistusertib (AZD2014) | N/A | Recurrent Grade II-III Meningiomas | Phase 2 | NCT03071874 |
| Everolimus | Levonorgestrel-Releasing Intrauterine System | Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer | Phase 2 | NCT02397083 |
| AZD2014 | Rituximab | Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | NCT02752204 |
| MLN0128 | MLN1117 oral inhibitor of the PI3K (alpha) isoform | Advanced Nonhematologic Malignancies | Phase 1 | NCT01899053 |
|
Milled MLN0128 API |
Unmilled MLN0128 API and Paclitaxel | Advanced Nonhematologic Malignancies | Phase 1 | NCT02412722 |
| MLN2480 | MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan | Advanced Nonhematologic Malignancies | Phase 1B | NCT02327169 |
| AZD2014 | Paclitaxel |
Ovarian cancer Squamous cell lung cancer |
Phase 1 | NCT02193633 |
| TAK228 | Paclitaxel |
advanced/Recurrent Epithelial Ovarian, Fallopian Tube Primary Peritoneal Cancer |
Phase 2 | NCT03648489 |
| Sirolimus | N/A | Cardiovascular Abnormalities/Vascular Malformations | Phase 3 | NCT01811667 |
| AP23573 (Ridaforolimu) | N/A | Advanced Sarcoma | Phase 2 | NCT00093080 |
| Rapamycin | Placebo | Aging and associated complications | Phase 2 | NCT02874924 |
| Everolimus | Imatinib mesylate | Metastatic or Unresectable Kidney Cancer | Phase 2 | NCT00331409 |
| MLN0128 | Paclitaxel; Trastuzumab | Advanced Solid Malignancies Hematologic Malignancies | Phase 1 | NCT01351350 |
| WXFL10030390 | N/A |
Advanced Solid Tumors Lymphoma |
Phase 1 | NCT03730142 |
| Metformin | N/A | Well-differentiated Neuroendocrine Tumors | Phase 2 | NCT02279758 |
| SF1126 | N/A | Advanced or Metastatic Solid Tumors | Phase 1 | NCT00907205 |
| Everolimus | N/A | Chronic Allograft Dysfunction in Renal Transplantation | Phase 4 | NCT01046045 |
| Sirolimus | N/A | Congenital Vascular Malformations | Phase 3 | NCT03987152 |
| Sirolimus | N/A | Peutz-Jeghers Syndrome | Phase 4 | NCT03781050 |
| RAD001 (Everolimus) | N/A | Tuberous Sclerosis Lymphangioleiomyomatosis | Phase 1 & 2 | NCT00457964 |
| RAD001 (Everolimus) | N/A |
Subependymal Giant Cell Astrocytoma Tuberous Sclerosis |
Phase 1 & 2 | NCT00411619 |
| RAD001 (Everolimus) | N/A |
Epilepsy Tuberous Sclerosis Complex |
Phase 1 & 2 | NCT01070316 |
| Sirolimus | Placebo |
Polycystic Kidney, Type 1 & Type 2 Autosomal Dominant Disease |
Phase 3 | NCT02055079 |
| Sirolimus | N/A |
Blue Rubber Bleb Nevus Syndrome Hereditary Sporadic Venous Malformation |
Phase 4 | NCT03767660 |
| Gedatolisib | Palbociclib/Letrozole Or Palbociclib/Fulvestrant | Metastatic Breast Cancer | Phase 1B | NCT02684032 |
|
Arm 1 Everolimus/ tacrolimus |
Calcineurin inhibitors | Renal Transplant and associated complications | Phase 4 | NCT01935128; [80] |
| RAD001 (Everolimus) | Placebo | Tuberous Sclerosis Complex (TSC) Lymphangioleiomyomatosis (LAM) | Phase 3 | NCT00790400; [80] |
| CCI-779 (Temsirolimus) | N/A | Breast and Renal cancer | Phase 2 | [73] |
ClinicalTrials ID has been taken from https://clinicaltrials.gov